$10.77 0%
Price vs. AI Score (Last 150 days)
Data gathered: November 30

Data Bits

Data Bits Value / Change Benchmark
Job Posts 15 0%
Sentiment 80 -5.9%
Webpage traffic 25,000 24.3%
Employee Rating 71 0%
Google Adspend $ N/A N/A
Google Trends 31 -11.4%
Linkedin Employees 275 N/A
Patents 84 0%
4chan Mentions 0%
Stocktwits Mentions 4 0%
Stocktwits Subscribers 16,913 -0%
News Mentions 0%
Reddit Mentions 0%
ESG 43 -2.3%
Business outlook 57 0%

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

In the news

About Editas Medicine

Editas Medicine is a clinical-stage biotechnology company which is developing therapies based on CRISPR–Cas9 gene editing technology. Editas is based in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

Editas Medicine
Price $10.77
Target Price Sign up
Market Cap $864M
Dividend Yield 0
Industry Biotechnology

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda
Q3 '235.3M15M-9.7M-45M-45M
Q2 '232.9M17M-14M-40M-44M
Q1 '238.3M23M-15M-49M-51M
Q4 '226.5M18M-11M-61M-63M
Q3 '2242,00016M-16M-56M-56M

Insider Transactions

Eaton Bruce filed to sell 74,894 shares at $8.2.
November 16 '23
Eaton Bruce filed to sell 75,589 shares at $8.4.
November 9 '23
Eaton Bruce filed to sell 75,728 shares at $8.8.
September 7 '23
Eaton Bruce filed to sell 75,831 shares at $8.6.
August 15 '23
Eaton Bruce filed to sell 76,533 shares at $8.4.
August 10 '23
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2023 AltIndex. All rights reserved.